The Bexsero vaccine will become part of the immunisation schedule from September 1 2015, according to Public Health England.
In England, babies will be able to receive the Bexserro vaccine to protect them from Meningococcal Group B (MenB) disease, which is one of the leading causes of meningitis and septicaemia.
Meningococcal Group B bacteria can cause severe illnesses for children, with some cases resulting in brain damage, amputation of limbs or death.
The Bexsero vaccine will protect children from getting infected with Meningococcal Group B bacteria, which is 90% responsible for infections in young children.
Babies aged between two and four months will be given the vaccine, as part of routine vaccinations already available, under the NHS.
On the Public Health England blog, it says: “In short, the vaccine will save lives and help prevent permanent disability. Parents however may have some concerns, therefore nurses and midwives – particularly health visitors and general practice nurses – have a crucial role to play in supporting and advising parents.”
It has been suggested the Bexsero vaccine has a positive safety record; however, there is a risk of fever when it is given alongside other vaccinations, therefore paracetamol should be used following the immunisation process.
According to tests, the fever can peak around 6 hours after vaccination, before symptoms start to reduce within two days.
However, symptoms of fever and its longevity depend on the individual child.
Public Health England recommends midwives to direct parents to information about the MenB vaccination before their two-month vaccination appointment.
Keep up to date with the latest news from MIDIRS by signing up to our e-newsletter. Sign-up
Image: Kurt Kleemann @Fotolia